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in theranostic nanomedicines.[1] The nano-
medicine will particularly play a role in 
the emerging era of personalized treat-
ment by offering improved prognoses. 
Three key components are often required 
to formulate a theranostic nanomedicine: 
therapeutic drug, imaging agent, and their 
delivery vehicle.[2]
Delivery vehicles have been explored 
from a myriad of materials, including 
lipids, peptides, proteins, synthetic or nat-
urally derived polymers, carbon, metals, 
and metal oxides.[3g,h] Synthetic polymers 
with different architectures, such as linear, 
star, branched, and dendritic shapes as 
well as supramolecular assemblies, have 
been employed for tumor specific diag-
nosis and therapy.[4] Several formulations 
have received market approval.[5] For 
example, hydrophobic anticancer drugs 
are conjugated to the poly[N-(2-hydroxy-
propyl) methacrylamide] (pHPMA) via a 
stimuli-sensitive linker because pHPMA 
is nontoxic, nonimmunogenic, and non-
biodegradable during circulation.[6] The 
pHPMA-drug conjugates have improved 
water solubility of the drug, increased drug bioavailability, 
achieved controllable drug release, prolonged the half-life of the 
conjugate in plasma, and enhanced accumulation of the drug 
in tumor tissues, leading to an improved antitumor efficacy 
A stimuli-responsive polymeric prodrug-based nanotheranostic system with 
imaging agents (cyanine5.5 and gadolinium-chelates) and a therapeutic agent 
paclitaxel (PTX) is prepared via polymerization and conjugating chemistry. The 
branched polymeric PTX-Gd-based nanoparticles (BP-PTX-Gd NPs) demon-
strate excellent biocompatibility, and high stability under physiological condi-
tions, but they stimuli-responsively degrade and release PTX rapidly in a tumor 
microenvironment. The in vitro behavior of NPs labeled with fluorescent dyes 
is effectively monitored, and the NPs display high cytotoxicity to 4T1 cells 
similar to free PTX by impairing the function of microtubules, downregulating 
anti-apoptotic protein Bcl-2, and upregulating the expression of Bax, cleaved 
caspase-3, cleaved caspase-9, cleaved-PARP, and p53 proteins. Great improve-
ment in magnetic resonance imaging (MRI) is demonstrated by these NPs, 
and MRI accurately maps the temporal change profile of the tumor volume 
after injection of NPs and the tumor treatment process is also closely cor-
related with the T1 values measured from MRI, demonstrating the capability 
of providing real-time feedback to the chemotherapeutic treatment effective-
ness. The imaging-guided chemotherapy to the 4T1 tumor in the mice model 
achieves an excellent anti-tumor effect. This stimuli-responsive polymeric 
nano-agent opens a new door for efficient breast cancer treatment under the 
guidance of fluorescence/MRI.
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Integration of diagnostic and therapeutic modalities within one 
polymeric drug delivery system has been attempted to be realized 
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and decreased inherent toxicity.[7] Currently, several HPMA 
polymer-drug conjugates are undergoing clinical trials, 
however, their low molecular weights (MWs) and short circu-
lation time in vivo have hampered their clinical applications 
because the MWs must be controlled below the renal threshold 
(<50 kDa) to ensure biosafety of the polymer.[8]
Recently, biodegradable HPMA polymeric conjugates with 
MWs of 100–300 kDa have been prepared with enhanced 
accumulation in tumors and increased therapeutic indexes, 
while they still maintain excellent biosafety.[9] In our pre-
vious studies, biodegradable high MWs branched pHPMA 
polymers have been demonstrated with high accumulation 
in tumors and excellent biosafety.[10] Branched pHPMA 
polymers have exhibited special characteristics, such as 
self-assembly properties, easy preparation, a unique topo-
logical structure, and more functional groups for conjuga-
tion.[11] More functional groups allow covalent conjuga-
tion with multimodal agents, including therapeutic agents 
and imaging probes. In addition, these branched polymers 
are generally prepared via one-pot reversible addition-
fragmentation chain transfer (RAFT) polymerization, so 
synthesis and purification of these polymers are ready for 
scale-up manufacture. Although our previously reported 
branched pHPMA-based drug delivery systems have shown 
enhanced anticancer activities compared to free drugs,[10,11b] 
improvements in the therapeutic indexes may be achieved 
via optimization of its molecular structure and conjugated 
agents.
The imaging modality has been exploited by specific mole-
cular probes or contrast agents. Magnetic resonance imaging 
(MRI), one of the most commonly used medical diagnostic 
techniques, possesses unique features including noninva-
siveness, no exposure to ionizing radiation, high contrast 
in soft tissues, and high spatiotemporal resolution.[12] MRI-
based polymeric theranostics have been extensively studied 
including contrast agents and polymers, such as gadolinium-
tetraazacyclododecanetetraacetic acid (Gd-DOTA), gado-
linium-diethylenetriamine penta-acetic acid (Gd-DTPA), poly-
peptides, pHPMA, polyamido-amine dendrimers (pAMAMs), 
etc.[13] Although pAMAMs conjugated with contrast agents 
have been observed with high relaxivity, efficient loading, and 
enhanced contrast, inherent toxicity of pAMAMs prevents 
further development of the dendrimer-based conjugate.[14] 
Optical imaging by covalently attaching fluorescent probes 
such as small fluorophores and fluorescent proteins to a 
polymer offers high image sensitivity, low bleaching rate, and 
low toxicity to cells, and living organisms, allowing effective 
evaluation of drug delivery process and intracellularly moni-
toring the tempospatial profile of the administrated drug.[15b] 
MRI provides macroscopic information with a submillimeter 
spatial resolution, and fluorescence imaging detects micro-
cosmic details at a subcellular level.[16] A combination of MRI 
and fluorescence imaging is a very promising multimodal 
imaging strategy for theranostics. Many elaborately designed 
systems have been reported for in vivo simultaneous MRI 
and fluorescence imaging.[17] However, to our knowledge, 
there are currently very few biodegradable branched polymer-
based nanomedicines that combine multimodal imaging with 
tumor therapy for cancer research.
Herein, we proposed to construct a novel biodegradable 
multifunctional theranostic nanoplatform based on branched 
polymers for simultaneous diagnosis and treatment of breast 
cancer. By integrating a Gly-Phe-Leu-Gly (GFLG) tetrapeptide, 
an anticancer drug PTX, a fluorescence dye cyanine5.5 (Cy5.5), 
and an MRI contrast agent Gd-DOTA into a branched pHPMA 
polymer through RAFT polymerization, click chemistry, and 
chemical complexation (Scheme 1a) , the as-prepared product 
would self-assemble into a theranostic nanomedicine (BP-PTX-
Gd NPs) (Scheme 1b). After the nanomedicine was uptaken 
by tumor cells, it would be capable of offering both MRI and 
fluorescence imaging (Scheme 1c) and releasing the anticancer 
drug for chemotherapy (Scheme 1d). The polymer backbone 
would be degraded into small fragments in the presence of 
overexpressed cathepsin B in the tumor cellular microenviron-
ment (Scheme 1d) and the small fragments would be cleared to 
avoid toxic buildup of the delivery vector and the MRI contrast 
agent in the body. This cathepsin B-responsive biodegradable 
theranostic nanomedicine derived from the branched pHPMA 
polymer could be formulated with other anticancer drugs for a 
variety of diseases.
2. Results and Discussion
2.1. Preparation and Characterization of BP-PTX-Gd NPs
The proposed theranostic nanomedicine for simultaneous diag-
nosis and treatment was prepared with the detailed synthesis 
route shown in Figure S1 in the Supporting Information: the 
branched polymer backbone was synthesized by the one-pot 
method using RAFT polymerization using enzyme-responsive 
chain transfer agents; the anticancer drug PTX was loaded onto 
the branched polymer via an enzyme-responsive linker; Cy5.5 
for fluorescence imaging was attached to the polymer chain via 
thiol-ene click reaction and the MRI contrast agent Gd(III) che-
lated in DOTA was covalently bound to the polymer side chain. 
The GFLG peptide-containing degradable dimethacrylate mon-
omer, MA-GFLGK-MA, was used as a crosslinker. MA-GFLG-
CTA simultaneously acted as a chain transfer agent (CTA) and 
a monomer due to the existence of two functional groups: a 
dithiobenzoate group and a methacrylate group. Therefore, the 
degradable drug-loaded branched pHPMA was obtained from 
one-step reaction. After purification, the dithiopyridine group 
in the polymer was removed by dithiothreitol (DTT) to reveal 
the thiol groups for covalently binding to the maleimide Cy5.5 
through a highly efficient thiol-ene click reaction. Finally, the 
obtained Cy5.5-labeled polymer was chelated with GdCl3·6H2O 
to yield the proposed product.
The structure of the as-prepared BP-PTX-DOTA conjugate 
was characterized by proton nuclear magnetic resonance (1H 
NMR) spectroscopy, energy dispersive X-ray spectroscopy (EDX), 
Fourier transform infrared (FTIR) analysis, and amino acid 
analysis. The molecular weight and polydispersity index (PDI) 
were determined by size exclusion chromatography. As shown 
in Figure 1a, the resonance signals at 1.5–0.6 and 5.0–2.8 ppm 
assigned to the protons of CH, CH2, CH3, and OH 
are associated with pHPMA units. The signals appearing at 
2.7–1.6 ppm are ascribed to the protons of CH2 in both 
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MA-DOTA and MA-GFLG-PTX units. The aromatic protons 
derived from MA-GFLGK-MA and MA-GFLG-PTX units pro-
duce peaks at 8.7–7.0 ppm. The elements in the BP-PTX-Gd 
conjugates include N, S, O, and Gd shown in Figure 1b from 
EDX analysis. Compared to the gadolinium-free polymer, FTIR 
spectra showed that the characteristic peak of the carboxyl 
group (3337.28 and 1717.78 cm−1) in the BP-PTX-Gd conjugates 
changed significantly (Figure S2, Supporting Information), 
indicating that Gd(III) was successfully chelated into DOTA. 
The characteristic peak of Cy5.5 is observed in both ultravi-
olet–visible (UV–vis) and fluorescence spectra of Cy5.5-labeled 
conjugate compared to the unlabeled conjugate (Figure 1c), 
confirming that the fluorescent dye has been successfully cova-
lently attached to the conjugate. The amino acid analysis reveals 
that the molar ratio of glycine (Gly), phenylalanine (Phe), and 
leucine (Leu) in the conjugate is about 2:1:1 (Table S1, Sup-
porting Information), which is consistent with the amino acid 
ratio in the monomers, indicating the presence of enzyme-
responsive GFLG tetrapeptides in the polymer backbone. In 
addition, the molecular weight of the BP-PTX-Gd conjugate is 
186 kDa with a PDI of 2.30 (Table S1, Supporting Information).
The morphology of the polymer conjugate-based nanoparti-
cles was detected by dynamic light scattering (DLS) and scanning 
electron microscope (SEM), respectively. As shown in Figure 1d, 
the BP-PTX-Gd NPs have an intensity-weighted average 
hydrodynamic diameter of about 62.6 ± 1.1 nm and a surface 
charge of −7.75 ± 0.35 mV from DLS measurements, and the 
size is also confirmed from SEM (about 50 nm, Figure 1e). It is 
noted that nanoparticles are well dispersed in water from SEM. 
By varying the nanoparticles concentration (Figure 1f), the BP-
PTX-Gd conjugate aggregates into nanoparticles at a very low 
concentration with a critical aggregation concentration (CAC) of 
≈15.3 µg mL−1. The balance between hydrophilic interaction and 
hydrophilic interaction is one of the main driving forces for nan-
oparticle self-assembly. In this study, the main reason for the 
formation of nanoparticles by BP-PTX-Gd conjugate may be the 
hydrophilic and hydrophobic effects, because there are many dif-
ferent hydrophilic segments (Gd-DOTA and HPMA) and hydro-
phobic segments (GFLG, PTX, Cy5.5) in the polymer structure. 
In addition, some other driving forces should also be consid-
ered, including hydrogen bonding, π–π stacking, dipole interac-
tion, etc., because the hydrophobic part of a branched polymer 
is composed of multiple domains with different chemical com-
positions, such as aromatic and aliphatic groups. For stability 
analysis, the size of BP-PTX-Gd NPs slightly increases and the 
PDI has negligible changes after incubation for 72 h in phos-
phate buffer saline (PBS) with 10% fetal bovine serum (FBS) 
(Figure 1g), indicating that the formed nanoparticles may keep 
its integrated structure in the in vivo circulation system. It is 
worth noting that either the imaging moiety or PTX is covalently 
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Scheme 1. Schematic illustration of cathepsin B-responsive biodegradable theranostic nanomedicine derived from branched pHPMA. a) Chemical struc-
ture of branched pHPMA-PTX-Gd conjugates. b) BP-PTX-Gd NPs formed through self-assembly of the conjugate with hydrophilic and hydrophobic 
moieties. c) MR imaging in vivo of the delivery process of BP-PTX-Gd NPs to tumor sites via the EPR effect. d) BP-PTX-Gd NPs uptake and intracellular traf-
ficking through lysosomal endocytosis pathways, and intracellular biodegradation in the overexpressed cathepsin B microenvironment and controlled drug 
release. Then, the released PTX inhibited cell mitosis by stabilizing microtubules and activated the corresponding apoptotic pathway to induce apoptosis.
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linked to the pHPMA side chain, which further ensures the sta-
bility of BP-PTX-Gd NPs under physiological conditions. More-
over, the BP-PTX-Gd NPs have a nearly neutral surface charge 
and a size between 10 and 200 nm, which 
may help achieving low reticuloendothelial 
cell (RES) uptake, reduced renal excretion, 
and increased accumulation in tumor sites 
due to the enhanced permeability and reten-
tion (EPR) effect.
2.2. Degradation, Drug Release, and 
Relaxivity of BP-PTX-Gd NPs
The enzyme-dependent degradation of 
BP-PTX-Gd NPs was investigated by incu-
bation in a simulated tumor cellular micro-
environment at a cathepsin B concentration 
of 2.8 × 10−6 m and pH of 5.4. A PBS buffer 
at pH 7.4 was used as a control. The decrease 
in the MW of the branched polymers is incu-
bation-time dependent and the smallest frag-
ments with a MW of around 25 kDa and a 
smaller PDI are produced after an incubation 
time of 12 h (Table S2, Supporting Informa-
tion). A typical peak shift in the SEC chroma-
togram is shown in Figure 2a at an incubation 
time of 12 h. After degradation, the peak shifts 
toward a high value of the elution volume. 
However, the size and PDI of the conjugate in 
the control condition are nearly identical after 
incubation up to 18 h (Table S2, Supporting 
Information). Previous studies have shown 
that the HPMA-based polymer carrier with a 
high MW can reduce the renal clearance and 
increase the buildup at the tumor sites, how-
ever, the MWs of a polymer carrier above the 
renal threshold (≈50 kDa) may result in unde-
sirable accumulation of these high MW car-
riers in the body.[8c] Biodegradability of these 
high MW polymer carriers is often sought 
to address this undesirable accumulation in 
the issue. In our work, since the crosslinking 
agent used in the synthesis of the branched 
pHPMA polymers contains a GFLG tetrapep-
tide that is cleavable in the presence of cath-
epsin B, the branched pHPMA polymers are 
degraded to low MW fragments in the tumor 
cell microenvironment, which facilitates clear-
ance of the carrier from the body and reduces 
its potential toxicity.
The accumulated release of PTX from BP-
PTX-Gd NPs in a simulated tumor cellular 
microenvironment at 4 h reaches around 
67%, much higher than that under a physi-
ological condition (≈8%) (Figure 2c). Com-
pared to the physiological condition, PTX 
released from the nanoparticles is not detect-
able in the absence of cathepsin B at pH 5.4. 
This result is consistent with previous reports: the ester bond 
between PTX and pHPMA has great stability under a weakly 
acidic condition.[18] The released PTX from the nanoparticles 
Adv. Sci. 2020, 7, 1903243
Figure 1. Chemical structure characterization and physicochemical properties of BP-PTX-Gd 
NPs. a) 1H NMR of branched pHPMA-PTX-DOTA conjugate. Each peak labeled with letters 
a–p is assigned to the corresponding bonds in the chemical structure of the conjugate. b) EDX 
spectrum of the branched pHPMA-PTX-Gd conjugate. The peak for each element is assigned 
from the standard references. c) UV–vis and fluorescence spectra of the branched pHPMA-
PTX-Gd conjugate (dissolved in dimethyl sulfoxide) before and after addition of Cy5.5. d) Size 
distribution and zeta potential of BP-PTX-Gd NPs in aqueous solution determined by DLS. 
e) SEM image of BP-PTX-Gd NPs. f) CAC of BP-PTX-Gd NPs. g) Temporal changes in size 
and PDI of the BP-PTX-Gd NPs in PBS with 10% FBS for 72 h. The values are presented as the 
average ± standard deviation (n = 3).
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has the same peak as the original PTX in both high performance 
liquid chromatography (HPLC) and electrospray ionization 
mass spectrometry (ESI-MS) (Figure 2b,d).
Next, in order to assess the MRI capabilities of the BP-PTX-
Gd NPs, we analyzed the T1 weighted spin-echo MR imaging 
of BP-PTX-Gd NPs and Gd-DTPA using a clinical 1.5 T MRI 
scanner. As shown in Figure 2e, with a gradual increase in 
the Gd(III) concentration, incremental changes in the bright-
ness are clearly observed for both nanoparticles and Gd-DTPA, 
which means that the MR signal is positively enhanced with 
an increased Gd(III) concentration. Compared to Gd-DTPA, 
the BP-PTX-Gd NPs solution displays significantly enhanced 
MRI signal contrast at the same Gd(III) concentration. This 
result is consistent with the widely accepted fact that covalent 
attachment of Gd(III) complexes to polymers can significantly 
enhance the MRI contrast.[19] Quantitative analysis shows that 
there is a linear relationship of (1/T1) versus Gd(III) concen-
tration for both BP-PTX-Gd NPs and Gd-DTPA solutions 
(Figure 2f). The r1 value of the BP-PTX-Gd NPs is 8.6 mm−1 S−1, 
about 2.4 times that of Dd-DTPA, which further suggests that 
the BP-PTX-Gd NPs significantly enhances the MRI contrast.
2.3. Cell and Tumor Spheroids Uptake of BP-PTX-Gd NPs
The uptake of BP-PTX-Gd NPs by 4T1 cells was studied by 
confocal laser scanning microscopy (CLSM) and flow cytom-
etry with Cy5.5 as a fluorescent probe. As shown in Figure 3a, 
as the incubation time of BP-PTX-Gd NPs with 4T1 cells is 
extended from 1 to 5 h, the fluorescence intensity of Cy5.5 (red) 
in the cytoplasm gradually increases. The results of quantitative 
analysis by flow cytometry further confirm the time-dependent 
internalization of BP-PTX-Gd NPs by 4T1 cells (Figure S3, Sup-
porting Information). As shown in Figure 3b, the penetration 
of BP-PTX-Gd NPs into the 4T1 tumor spheroids is also time 
dependent. As the incubation time increases, the fluorescence 
intensity in the tumor spheroids increases significantly, which 
is consistent with the results from quantitative analysis by 
flow cytometry (Figure S4, Supporting Information). Through 
tomography, it can be found that BP-PTX-Gd NPs are pen-
etrated into the tumor spheroids gradually from the periphery 
into the core as the incubation time extends (Figure S5, Sup-
porting Information). The fluorescence intensity of BP-PTX-Gd 
NPs in the tumor spheroids has been significantly enhanced 
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Figure 2. Cathepsin B-responsive drug release and degradation of BP-PTX-Gd NPs. a) SEC profile of BP-PTX-Gd conjugates and their degraded prod-
ucts after incubation of the conjugate (3 mg mL−1) in PBS (pH 5.4) containing 2.8 × 10−6 m cathepsin B for 12 h at 37 °C. b) HPLC chromatograms 
of BP-PTX-Gd NPs with or without cathepsin B (2.8 × 10−6 m), free PTX as a control. c) PTX release profiles of the BP-PTX-Gd NPs in different buffer 
solutions at 37 °C. The values are presented as the average ± standard deviation (n = 3). d) ESI-MS analysis of released compounds. e) T1 weighted MR 
images of Gd-DOTA and BP-PTX-Gd NPs in PBS with different Gd (III) concentration. f) Water proton longitudinal relaxation rate (1/T1) of Gd-DTPA 
and BP-PTX-Gd NPs in PBS as a function of Gd (III) concentration.
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after 5 h of incubation compared to 1 h incubation. The above 
results indicate that the BP-PTX-Gd NPs are gradually and effi-
ciently endocytosed by 4T1 cells.
To distinguish the entry pathway of BP-PTX-Gd NPs into 
4T1 cells, the cellular uptake was re-examined in the presence 
of different inhibitors. As shown in Figure 3c, after 4T1 cells 
were treated at 4 °C or with sodium azide, the uptake rate of 
BP-PTX-Gd NPs decreases to 40.7% and 56.3%, respectively, 
indicating that the uptake of BP-PTX-Gd NPs by cells is an 
energy-dependent process. After treatment with nocodazole 
and genistein, the endocytosed nanoparticles in the 4T1 cells 
decreases to 77.6% and 81.6%, respectively, indicating that 
macropinocytosis and caveolin-mediated endocytosis are 
involved in the endocytosis process of BP-PTX-Gd NPs. It is 
worth noting that after the 4T1 cells are treated with chlorprom-
azine, the uptake of BP-PTX-Gd NPs is significantly restricted, 
and the uptake rate drops to 71.9%, indicating that the BP-PTX-
Gd NPs may be mainly internalized by the clathrin-mediated 
endocytosis. The key pathways for cellular uptake of BP-PTX-
Gd NPs include energy-dependent endocytosis, clathrin-medi-
ated endocytosis, caveolin-mediated endocytosis, and macrocy-
tosis. The multichannel uptake pathways enable BP-PTX-Gd 
NPs to be effectively delivered into 4T1 cells.
Previous studies have shown that nanoparticles internal-
ized by clathrin-mediated endocytosis will be located in lys-
osomes.[20] Therefore, the cellular drug delivery of BP-PTX-Gd 
NPs was monitored by detecting Cy5.5 in the BP-PTX-Gd NPs 
under a CLSM inside the 4T1 cells whose cell nuclei and lys-
osomes were stained by Hoechst 33342 (blue) and lysotracker 
(green), respectively. As shown in Figure 3d, after incubation 
of BP-PTX-Gd NPs with 4T1 cells for 1 h, strong red fluores-
cence is observed in the cytoplasm and it is coincidentally 
co-located with the green fluorescence of lysosomes. As the 
incubation time prolongs, more red fluorescence gradually dif-
fuses into the cytoplasm. At 5 h of incubation, red fluorescence 
has been significantly enhanced and widely distributed inside 
the cytoplasm, and it almost completely masks the lysosomal 
fluorescence. It can be seen that BP-PTX-Gd NPs gradually 
enter the tumor cells through the lysosome endocytic pathway, 
which may facilitate rapid release of covalently linked PTX 
under the action of cathepsin B overexpressed in lysosomes, 
and thus exert its antitumor effect.
Adv. Sci. 2020, 7, 1903243
Figure 3. a) CLSM images of 4T1 cells after treatment with Cy5.5-labeled BP-PTX-Gd NPs at different times. Hoechst 33342 (blue) for nuclei, and 
fluorescence dye Cy5.5 (red) for BP-PTX-Gd NPs. The scale is 50 µm. b) CLSM images of 4T1 tumor spheroids after treatment with Cy5.5-labeled BP-
PTX-Gd NPs at different times, red represents the fluorescence of Cy5.5. The scale is 100 µm. c) Percentage of BP-PTX-Gd NPs uptake by 4T1 cells at 
different inhibitor conditions (*p < 0.01). d) The lysosomal escape behavior of BP-PTX-Gd NPs at different times in 4T1 cells. Hoechst 33342 (blue) 
for nuclei, lysotracker (green) for lysosomal, and fluorescence dye Cy5.5 (red) for BP-PTX-Gd NPs. The scale is 10 µm.
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2.4. Cell Cytotoxicity and Induced Apoptosis
PTX binds to β-tubulin in the assembled tubulin, maintains the 
stability of microtubules, and suppresses microtubule dynamics, 
thereby inhibiting formation of mitotic spindles and leading to 
cell death. To confirm the effect of PTX on 4T1 cell microtubules, 
we analyzed the microtubule morphology of cells treated with dif-
ferent formulations under a CLSM. As shown in Figure 4a, in 
the control group, the microtubules of the cells are evenly distrib-
uted in the cytoplasm, while the microtubules of the cells treated 
with Taxol and BP-PTX-Gd NPs display aggregation around the 
nucleus. The nuclear structure of the control group is intact, 
however, more than one disintegrated nuclei are observed in the 
Taxol and BP-PTX-Gd NP-treated group, indicating that mitosis 
may be inhibited. Furthermore, compared with the filament 
structure of the control group, the microfilament structure in the 
drug treatment group appears to be damaged, evidenced with an 
incomplete microfilament structure, disordered arrangement, 
points, or a lump shape (Figure 4b). Western blot (WB) analysis 
reveals that compared with the control group, the amount of α/β-
Adv. Sci. 2020, 7, 1903243
Figure 4. a) Microtubules aggregation and b) microfilament damage of 4T1 cells after treatment with BP-PTX-Gd NPs and Taxol for 24 h. Red 
fluorescence for tubulin antibody, green for actin antibody, and blue for nuclear staining with DAPI. The scale is 10 µm. c) Western blot assay and 
d) semiquantitative analysis of α/β tubulin and pan-actin in the 4T1 tumor cells after incubation with Taxol and BP-PTX-Gd NPs for 24 h (*p < 0.01 
compared to control group). e) Cytotoxicity of BP-PTX-Gd NPs and Taxol against 4T1 cells after incubation for 48 h (means ± SD, n = 5). f) Cell cycle 
distribution and g) apoptosis of 4T1 cells after treatment with Taxol and BP-PTX-Gd NPs for 24 h. h) Western blot assay of Bcl-2, Bax, PARP, cleaved 
PARP, caspase-3, cleaved caspase-3, casepase-9, cleaved caspase-9, and p53 in the 4T1 tumor cells after incubation with Taxol and BP-PTX-Gd NPs for 
24 h. Cells treated with PBS were used as a control.
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tubulin in the cells treated by Taxol or BP-PTX-Gd NPs increases, 
while the amount of the pan-actin protein does not significantly 
change (Figure 4c,d). Therefore, Taxol or BP-PTX-Gd NPs are 
more likely to destroy the function of microtubules and microfila-
ments, rather than reduce their contents.
In the lysosomes, BP-PTX-Gd NPs are exposed to a tumor cel-
lular microenvironment with overexpressed cathepsin B at an 
acidic pH. PTX released from the BP-PTX-Gd NPs is toxic to 4T1 
cells. We used the cell counting kit-8 (CCK-8) method to detect 
the cytotoxicity against 4T1 cells induced by BP-PTX-Gd NPs. As 
shown in Figure 4e, with an increase in the PTX concentration, 
the cell viability after treatment with Taxol and BP-PTX-Gd NPs 
displays a significant decrease. The IC50 value of BP-PTX-Gd NPs 
(0.55 µg mL−1) is higher than that of Taxol (0.45 µg mL−1), which 
may be due to a more complex process of entry, trafficking, and 
drug release of BP-PTX-Gd NPs than free PTX.
Furthermore, we used DNA flow cytometry to analyze the 
effect of PTX released from nanoparticles on cell cycle distribu-
tion. As shown in the Figure 4f, the cells in the control group 
are mainly in the G0/G1 phase and the S phase, and the G2/M 
phase cells only account for 15.04%. After treatment with 
Taxol or BP-PTX-Gd NPs, the proportion of cells in the G2/M 
phase significantly increases, increasing to 53.42% and 38.54%, 
respectively. These results indicate that the PTX released from 
the nanoparticles has the same efficacy as free paclitaxel, 
arresting cells in the mitotic G2/M phase of mitosis, resulting 
in high cytotoxicity. Apoptosis of 4T1 cells incubated with Taxol 
and BP-PTX-Gd NPs by flow cytometry is shown in Figure 4g. 
Both BP-PTX-Gd NPs and Taxol are able to effectively induce 
4T1 cell apoptosis compared to the control group without any 
treatment, and a similar percentage of cells for induced apop-
tosis and necrosis (51.1% and 43.1%, respectively) is obtained 
for both groups. To study the mechanism of apoptosis, we used 
WB to analyze the intracellular content of apoptosis-related pro-
teins at the level of molecular biology. As shown in Figure 4h, 
the WB analysis shows that Taxol or BP-PTX-Gd NPs treat-
ment downregulates the level of antiapoptotic protein Bcl-2 in 
4T1 cells compared to the control group. At the same time, the 
level of Bax, cleaved caspase-3 protein, cleaved caspase-9, p53 
protein, and cleaved PARP protein in the cells is upregulated 
after treatment with Taxol or BP-PTX-Gd NPs, and semiquan-
titative analysis reveals that a significant difference of the these 
protein after treatment by both Taxol or BP-PTX-Gd NPs com-
pared with the control group (Figure S6, Supporting Informa-
tion). These results indicate that BP-PTX-Gd NPs have a similar 
mechanism of action as free paclitaxel, which is capable of dis-
turbing cell cycles and activating the corresponding apoptotic 
pathways, thereby significantly inducing apoptosis.
2.5. In Vivo Toxicity and Blood Compatibility of BP-PTX-Gd NPs
Excellent biocompatibility is critical to an ideal nanoscale drug 
delivery system. We first evaluated the hemocompatibility of 
BP-PTX-Gd NPs by detecting the morphology, aggregation, 
and hemolysis of red blood cells from healthy mice. Red color 
in the supernatant for red blood cells (RBCs) with BP-PTX-Gd 
NPs at a concentration of up to 4 mg mL−1 is not observable 
(Figure S7a, Supporting Information), and the percentage of 
hemolysis is around 3.5% at the maximum nanoparticle con-
centration (4 mg mL−1) for 12 h, which is lower than the accept-
able percentage of hemolysis (5%) (Figure S7b, Supporting 
Information). SEM images (Figure S8, Supporting Informa-
tion) further confirm that there is no obvious aggregation of 
RBCs after incubation with different concentrations of BP-
PTX-Gd NPs, and the structure of the erythrocyte membrane is 
intact in the presence of BP-PTX-Gd NPs. As the in vivo blood 
compatibility influences the nanoparticles biocompatibility 
and their further application as intravenous agents,[21] in this 
study, the blood routine analysis and blood biochemical studies 
showed the BP-PTX-Gd NPs have good blood compatibility 
(Figures S9 and S10, Supporting Information).
Furthermore, to evaluate the potential toxicity of BP-PTX-Gd 
NPs to normal tissues and organs, healthy mice were treated 
with BP-PTX-Gd NPs for 21 d. The treated mice do not exhibit 
abnormal symptoms and behaviors (such as weight loss and 
listlessness, etc.) during the entire experiment period. The 
hematoxylin-eosin (H&E) staining of the main organs of the 
mice in the BP-PTX-Gd NPs treatment group does not reveal 
significant pathological changes in each organ (Figure S11, 
Supporting Information). Inherent toxicity and off-target accu-
mulation of the theranostic nanoparticles are major concerns 
for clinical applications. We have demonstrated low in vivo tox-
icity of BP-PTX-Gd NPs to major organs and great hemocom-
patibility. Excellent biosafety of the nanomedicine lays the solid 
foundation for its multimodal functions. The biosafety may 
stem from its unique structure and degradation in the tumor 
specific microenvironment as pHPMA polymers have been 
intensively studies as a biocompatible polymer carrier.[22]
2.6. Pharmacokinetics and Biodistribution
Figure 5a shows the plasma pharmacokinetic profiles of Gd(III) 
in BP-PTX-Gd NPs and Gd-DTPA-treated mice. For the small 
molecule Gd-DTPA, the concentration of Gd(III) in the blood 
descends rapidly to a very low level within 1 h. In contrast, the 
concentration of Gd(III) in the blood of mice treated with BP-
PTX-Gd NPs reduces relatively slower. The in vivo blood circula-
tion time of BP-PTX-Gd NPs is remarkably prolonged, and the 
half-life time (t1/2) for BP-PTX-Gd NPs is 50.5-fold longer than 
that of Gd-DTPA (13.63 and 0.27 h, respectively) (Table S3, Sup-
porting Information). In addition, the results of angiography 
in mice obtained by MRI are consistent with those of pharma-
cokinetic experiments. Compared with small molecule contrast 
agents Gd-DTPA, BP-PTX-Gd NPs are still visible in the blood 
circulation system up to 4 h after injection, and blood vessel 
structure is also clearly distinguished in the BP-PTX-Gd NP-
injected group (Figure S12, Supporting Information). The pro-
longed circulation time contributes to an increase in passive 
accumulation of the nanomedicine at the tumor site, resulting 
in enhanced imaging and therapeutic effects. The significantly 
prolonged blood half-life (t1/2) of BP-PTX-Gd NPs is due to a 
high MW of the nanomedicine, stable linkers in the chemical 
structure, a slightly negatively charged surface, and a branched 
structure with excellent chain flexibility and deformability.
The Gd(III) content in the heart, liver, spleen, lung, kidney, 
and tumor of tumor-bearing mice at 24 h postadministration of 
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Figure 5. a) In vivo pharmacokinetic data of Gd (III) concentration after intravenous injection of BP-PTX-Gd NPs and Gd-DTPA, respectively (means ± 
SD, n = 5). b) Biodistribution of Gd(III) in major organs and tumors at 24 h postinjection of Gd-DTPA in 4T1 tumor-bearing mice (n = 5). c) Biodistribu-
tion of Gd(III) in major organs and tumors at 24 and 120 h postinjection of BP-PTX-Gd NPs in 4T1 tumor-bearing mice (means ± SD, n = 5). d) In vivo 
MR images of mice bearing subcutaneous 4T1 tumors after intravenous injection of BP-PTX-Gd NPs and Gd-DTPA at different time points. e) Relative 
MR enhanced signal intensity (SI) in tumor sites after injection of BP-PTX-Gd NPs and Gd-DTPA. *p < 0.01 compared to Gd-DTPA (means ± SD, 
n = 5). f) Ex vivo fluorescent imaging of tumors and major organs harvested from the Cy5.5-labled BP-PTX-Gd NP-treated mice. g) Average signals 
from major organs and tumors at different time points after injection of Cy5.5-labled BP-PTX-Gd NPs (means ± SD, n = 5). h) Confocal microscopy 
of time-dependent extravasation and penetration of BP-PTX-Gd NPs (purple) in 4T1 tumors at intervals after the injection. Scale bars = 200 µm.
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Gd-DTPA is shown in Figure 5b. The highest Gd(III) content 
is found in the kidney after 24 h, and it is only 0.5%. In con-
trast, a higher level of Gd(III) content is detected in liver and 
spleen in the BP-PTX-Gd NPs group (20.9% and 13.2%, respec-
tively) (Figure 5c), which is consistent with previous reports 
that pHPMA polymers with a high MW are prone to accumula-
tion in the liver and spleen.[23] Furthermore, the tumor in the 
BP-PTX-Gd NP-treated mice contains a relatively high Gd(III) 
content of 6.3%, which supports that the theranostic nanomedi-
cine is effectively accumulated at tumor sites. To further eval-
uate the metabolism of BP-PTX-Gd NPs in mice, the Gd(III) 
content at each organ and tumor in mice was measured at 
120 h postadministration. As shown in Figure 5c, the Gd(III) 
level in all tissues has significantly decreased in comparison 
with that on the first day postinjection. The low Gd(III) resi-
dues in mice indicate that BP-PTX-Gd NPs may be excreted 
from body, which is consistent with the results of ex vivo 
fluorescence imaging, and this clearance may be attributed 
to biodegradability of the nanomedicine. This is also of great 
significance for confirming the biosafety of the nanoscale 
branched pHPMA-based MRI contrast agent.
2.7. MR and Fluorescence Imaging
The imaging function of BP-PTX-Gd NPs was further evaluated 
at tumor sites in BALB/c female mice bearing subcutaneous 
4T1 tumors by a 3 T scanner. As shown in Figure 5d, after 
30 min of administration, the tumor signal intensity (SI) in 
both BP-PTX-Gd NPs and Gd-DTPA-treated groups remarkably 
increases. The relatively enhanced MRI SI of BP-PTX-Gd NPs 
and Gd-DTPA is 214% and 191%, respectively, in comparison 
with an SI of around 150% at preinjection (Figure 5e). However, 
for the Gd-DTPA group, the SI at the tumor site dramatically 
decreases when the administration time exceeds 30 min. At 
4 h postadministration, SI has reduced to the level before admin-
istration. In contrast, for mice injected with BP-PTX-Gd NPs, 
the SI at the tumor site gradually increases as time increases 
during the experiment, and the highest relatively enhanced 
MRI value (about 275%) is reached after 24 h of administration. 
Compared to the small molecule Gd-DTPA, which is rapidly 
eliminated from the body via renal excretion, BP-PTX-Gd NPs 
have a bright contrast intensity, and the MRI signal maintains 
its brightness after 24 h postinjection. This allows detection of 
the injected nanomedicine at the tumor sites in a noninvasive 
manner.
Cy5.5 is a fluorescence probe, which has a deeper tissue 
penetration and a lower autofluorescence signal,[24] and Cy5.5-
labeled nanoparticles are tracked by detection of Cy5.5 fluores-
cence for their tempospatial distribution in a specific organ or 
tissue, which allows a better understanding of the dynamic dis-
tribution of nanomedicine in the organs and tissues, and pos-
sible excretion pathways.[25] In this work, ex vivo fluorescence 
images and quantitative fluorescent signals of main organs and 
tumors of mice at different time points after injection of Cy5.5-
labeled BP-PTX-Gd NPs are shown in Figure 5f,g, respectively. 
As the time prolongs after administration, the fluorescence 
intensity at the tumor site increases to a peak at 24 h postinjec-
tion and then it starts to gradually decay, while the fluorescence 
intensity in the liver, spleen, lung, and heart has a monoto-
nously decreasing trend. Interestingly, the fluorescence inten-
sity at the kidney reaches the highest level at 12 h postinjection. 
The imaging results imply that BP-PTX-Gd NPs may gradually 
accumulate at the tumor site through the EPR effect and the 
degraded NPs may be excreted by kidney metabolism.
Further, we examined the vascular permeability of BP-PTX-
Gd NPs. As shown in Figure 5h, a very pronounced fluorescent 
signal of Cy5.5 is observed in the blood vessels of the tumor site 
at 1 h after administration through the tail vein, and the signal 
is mainly located in the tumor blood vessels. With prolongation 
of the postinjection time, the boundary between the vascular 
region and the nonvascular region becomes blurred. A gradual 
increase in the fluorescence intensity in the nonvascular region 
may be associated with leakage of the nanoparticles from the 
blood vessel to the tumor tissue through the EPR effect and 
accumulation of these nanoparticles in the tumor site. After 
6 h of administration, the fluorescence intensity in the tumor 
area is markedly strengthened, and it is almost impossible to 
distinguish between the vascular and nonvascular regions. This 
result indicates that BP-PTX-Gd NPs can rapidly leak from the 
blood vessel to the tumor tissue through abnormal tumor vas-
cular structures and accumulate in the tumor.
2.8. Imaging-Guided Antitumor Therapy
In vivo therapeutic efficacy was further determined in 4T1 
tumor-bearing mice treated with BP-PTX-Gd NPs or Taxol, 
while saline was used as a control. The change in the tumor 
volume was accurately detected by a high resolution 7.0 T 
small animal MRI scanner during the treatment. As shown 
in Figure 6a, after three administrations every 7 d, the MRI 
snapshots reveal that the tumor volume in the Taxol-treated 
group and the saline group gradually becomes larger during 
the treatment. In contrast, the tumor volume in the BP-PTX-
Gd NP-treated group significantly shrinks. These results are 
consistent with the relative tumor volume changes measured 
by the vernier caliper (Figure S13a, Supporting Information). 
The tumor volume is also shown quantitatively in Figure 6b. 
Taxol displays a weak inhibitory effect on tumor growth, and 
the average tumor volume in mice gradually increases from 
108 to 360 mm3 throughout the treatment period. In contrast, 
BP-PTX-Gd NPs significantly inhibit the growth of tumors. The 
average tumor volume in the NP-treated group before adminis-
tration is about 127 mm3, and the tumor volume starts to grad-
ually shrink after administration. On the 20th day, the average 
tumor volume reduces to 66 mm3, and the tumors in 2 mice 
are completely eradicated (Figure 6c), which may be attributed 
to passive accumulation of the branched pHPMA polymer-car-
ried PTX at the tumor sites to increase the drug dose, and rapid 
release of PTX from the polymers in the lysosomes to exert its 
therapeutic effects after uptake through the endocytosis path-
ways. MRI is able to accurately monitor changes in the mouse 
tumor volume during treatment. This detection method has 
obvious advantages compared with measurement of tumor 
size by vernier caliper: it can measure the volume changes of 
irregular shaped tumors more accurately, and provide real-time 
feedback for the treatment of tumors. Moreover, no significant 
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Figure 6. a) Representative MR images of tumor size at different time points for each treatment group of mice (tumors marked by red lines). 
b) Quantitative tumor volume changes of mice obtained by MRI after being treated with saline, Taxol, and BP-PTX-Gd NPs (n = 7, *p < 0.001 vs 
saline, *p < 0.001 vs Taxol). c) Images of the tumors harvested from the mice 21 d after the treatment. d) The tumor weight of tumor-bearing mice 
after treatment (*p < 0.001 vs saline, *p < 0.001 vs Taxol). e) Distribution of T1 value of tumor at different time points after injection. The results are a 
representative of three separate experiments. T1-map sequence: SE, TR = 15–500 ms, TE = 2.0 ms, matrix = 256 × 256, slice thickness = 2.0 mm, gap 
= 0.0 mm, and field of vision = 160 × 160 mm. f) T1-mapped images of mouse carcinoma in situ at different time points after injection with different 
formulations. Immunohistochemical analysis of g) CD31, h) Ki-67, and i) TUNEL assays for 4T1 tumors (mean ± SD, *p < 0.01).
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body weight loss is observed for mice treated with BP-PTX-Gd 
NPs (Figure S13b, Supporting Information), which further 
indicates negligible systemic toxicities of BP-PTX-Gd NPs.
After the experiment, all mice were euthanized to har-
vest the major organs and tumors. The tumors were weighed 
(Figure 6d), and the tumor growth inhibition (TGI, %) calcu-
lated from the tumor weight is presented in Figure S13c in the 
Supporting Information. The TGI up to 81.3% is obtained from 
BP-PTX-Gd NP-treated mice, while only 19.0% for Taxol-treated 
mice. To further evaluate the antitumor effects of BP-PTX-Gd 
NPs, we changed the method of administration to once every 
4 d (4 times in total). After increasing the therapeutic dose, 
the therapeutic effect of the nanoparticles is further improved, 
and 4 out of 7 tumors have been completely eliminated. The 
TGI reaches 93%, and no obvious systemic toxicity is observed 
(Figure S14, Supporting Information). Compared to our previ-
ously reported branched polymeric prodrug-based nanoparti-
cles (TGI 50–85%),[23,25] this system can significantly inhibit the 
tumor growth and some tumors can be completely eradicated, 
resulting in significantly enhanced therapeutic indexes. This 
may be due to optimized molecular structure, superior tumor 
targeting, and rapid drug release with enzyme responsiveness.
Previous studies have shown that the T1 values of the tumor 
site is related to its internal environment, so the therapeutic 
effect was also examined by monitoring changes in the T1 
values of the tumor site.[26] Figure 6e shows pseudocolor maps 
of tumor T1 values during treatment in different experimental 
groups. Figure 6f summarizes the changes in T1 values of 
tumor sites in each group of mice treated by different formula-
tions through a clinical 3.0 T MRI scanner. During the entire 
treatment period, the T1 values detected in the BP-PTX-Gd NP-
treated group reveals a gradual increase as the treatment time 
extends, while the T1 values of the tumor site of the saline group 
and the Taxol group displays the opposite trend. Because the 
tumor volume in the BP-PTX-Gd NP-treated group gradually 
decreases during the treatment process, supply of water and 
blood to the tumor extracellular matrix is reduced. The change 
in the tumor environment leads to an increase in the T1 value of 
the tumor site. In contrast, the tumor volume of the Taxol group 
and the saline group gradually expands during the treatment, 
and the extracellular water and blood supply to the tumor con-
tinuously increases, resulting in a continuous decrease in the 
T1 value.[27] These results are consistent with the trend of tumor 
volume changes monitored by MRI, further demonstrating that 
BP-PTX-Gd NPs can achieve effective tumor therapy in vivo.
Subsequently, we investigated the inhibition mechanism of 
BP-PTX-Gd NPs by analyzing angiogenesis (CD-31, an endothe-
lium cell marker), cell proliferation (Ki-67), and apoptosis 
(TUNEL) in tumor tissues by immunohistochemistry (IHC) 
staining (Figure S15, Supporting Information). The tumor 
microvessel density (MVD) derived from imaging analysis of 
the CD-31 stained tissue after injection of BP-PTX-Gd NPs is 
5.5, which is remarkably lower than that in the Taxol-treated 
group and the control group (10 and 11, respectively, p < 0.01) 
(Figure 6g). Ki-67 staining reveals that the tumor cell proliferation 
rate treated by BP-PTX-Gd NPs is significantly lower than that of 
both Taxol and control groups (Figure 6h). After TUNEL staining 
(Figure 6i), treatment with BP-PTX-Gd NPs efficiently increases 
the percentage of TUNEL-positive tumor cells (apoptotic cells). 
These above results demonstrate that BP-PTX-Gd NPs effectively 
inhibit tumor angiogenesis and tumor cell proliferation, and 
induce tumor cell apoptosis, thus they have an excellent anti-
tumor efficacy. Furthermore, histological analysis was used to 
detect cancer metastasis and potential toxicity of the theranostic 
nanomedicine. As shown in Figure S16 in the Supporting Infor-
mation, tumor metastasis is observed in the lung of the mice 
in the saline group and the Taxol-treated group. In contrast, 
no tumor metastasis is detected in the BP-PTX-Gd NP-treated 
group. No obvious pathological changes are observed in major 
organs after treatment by BP-PTX-Gd NPs, Taxol, and saline at 
day 21, indicating excellent biosafety of BP-PTX-Gd NPs.
3. Conclusion
In summary, biodegradable branched pHPMA-PTX-Gd-Cy5.5 
conjugate synthesized via “one-pot” RAFT polymerization is con-
stituted of branched pHPMA as a carrier, an anticancer drug, 
and two imaging agents: Gd-DOTA as a contrast agent for MR 
imaging and Cy5.5 as a near infrared fluorescent dye for fluores-
cence imaging. Cathepsin B-responsive tetrapeptide GFLG for 
bridging pHPMA and PTX-pHPMA polymer chains is cleaved in 
a tumor microenvironment, leading to generation of small MW 
polymeric segments and PTX release specifically in the tumor 
cells with an equivalent potency to free PTX. BP-PTX-Gd NPs 
have an extended in vivo circulation time and are effectively accu-
mulated at the tumor site, evidenced by pharmacokinetic analysis, 
MRI, and fluorescence imaging. BP-PTX-Gd NPs significantly 
increase the relaxation efficiency and enhance contrast inten-
sity in comparison with small MW contrast agents. BP-PTX-Gd 
NPs have performed much better than Taxol in eliminating 4T1 
murine breast cancer in the mice while they are safe to the healthy 
tissue/organs. These results demonstrate a promising potential of 
the as-synthesized nanoparticles as a theranostic polymer-based 
nanoscale medicine for treating a variety of cancer diseases.
4. Experimental Section
Materials, methods, experiments, other data, and associated references 
are available in the Supporting Information. All animal operation 
procedures were carried out with the approval of the ethics committee of 
West China Hospital, Sichuan University (No. 2018148A and 2018150A).
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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